&nbsp;

Drugs Used:

abemaciclib,

letrozole

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

SELP

Cancer Type:

Endocrine,

Thyroid

Intent: Palliative

Funding:

Exceptional Access Program

selpercatinib - For the treatments of advanced or metastatic RET fusion-positive differentiated thyroid carcinoma (DTC); and unresectable advanced or metastatic RET-mutant medullary thyroid cancer (MTC)

Drugs Used:

selpercatinib

Quick Link(s):

Regimen Monograph

Apr 2025

Regimen

FOLFIRI+PNTM

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Panitumumab - In Combination with Chemotherapy for Metastatic Colorectal, Small Bowel, or Appendiceal Cancer

New Drug Funding Program

Panitumumab - First-Line Treatment for Left-Sided Metastatic Colorectal Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

ABEMANAS

Cancer Type:

Breast

Intent: Adjuvant, Palliative

Funding:

Exceptional Access Program

ODB - General Benefit

anastrozole

Drugs Used:

abemaciclib,

anastrozole

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

ABEMEXEM

Cancer Type:

Breast

Intent: Adjuvant

Funding:

Exceptional Access Program

ODB - General Benefit

exemestane

Drugs Used:

abemaciclib,

exemestane

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

FEDR

Cancer Type:

Hematologic,

Myeloproliferative Neoplasms (MPNs)

Intent: Palliative

Funding:

Exceptional Access Program

fedratinib - For the treatment of splenomegaly and/or disease related symptoms of myelofibrosis according to clinical criteria

Drugs Used:

fedratinib

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

ATEZ(MNT)

Cancer Type:

Lung,

Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer

New Drug Funding Program

Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer

Drugs Used:

atezolizumab,

atezolizumab (subcut)

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

RITU(MNT-SC)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma

Drugs Used:

riTUXimab (subcut)

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

PEMB

Cancer Type:

Lung,

Non-Small Cell

Intent: Adjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Adjuvant Treatment for Non-Small Cell Lung Cancer

Drugs Used:

pembrolizumab

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

MIDO

Cancer Type:

Hematologic,

Rare Diseases

Intent: Palliative

Drugs Used:

midostaurin (Unfunded)

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

SILT

Cancer Type:

Hematologic,

Rare Diseases

Intent: Palliative

Funding:

New Drug Funding Program

Siltuximab - Multicentric Castleman’s Disease (MCD)

Drugs Used:

siltuximab